We are delighted to congratulate our ecosystem member Prosoma on successfully raising €4.4 million in Pre-Series A funding!
- The funding round was led by renowned health tech investors Impact Ventures and Verge HealthTech Fund, with participation from Convergence Partners, Smartlink Partners, and Simpact Ventures. Additionally, an €800,000 investment opportunity remains available in a second close, set to take place in Q1 2025.
- Founded in 2018, Prosoma is a pioneer in digital healthcare. Their flagship product, Living Well Plus, is the only clinically validated digital solution offering tailored behavioural and psychological support for cancer patients. Throughout 2024, Prosoma has assisted nearly 3,000 patients, fueled by collaborations with more than 35 strategic partners in the DACH region.
- The capital raised will be allocated towards expanding Prosoma’s operations within the DACH market and growing the sales team to support increased demand. The company is also preparing to establish a robust presence in the U.S. market, which includes pursuing new reimbursement pathways.
We are inspired by Prosoma’s remarkable achievements and proud to support their ongoing journey.